WALTHAM, Mass. , Sept. 24, 2024 /PRNewswire/ -- Nanomosaic, the multiplex and multi-omic marker analysis company, today announced major technical and commercial milestones for its Tessie system and assays optimized for gene therapy applications, evidencing the need for improved analytics across development and manufacturing processes.
To further steer the development of the company's technologies and contents for gene therapy applications, Dr Guangping Gao – a world-renowned expert in the field, will be joining the Nanomosaic Scientific Advisory Board. "As the field of gene therapy continues to develop, the creation of more tissue-specific vectors with improved safety and efficacy profiles established in models of increasing biological relevance, is critical to develop the next generation of gene therapies," said Guangping Gao , PhD, Professor of Microbiology and Physiological Systems, Penelope Booth Rockwell Professor in Biomedical Research, University of Massachusetts Medical School . "Novel technologies such as Nanomosaic's, recently acquired by my laboratory, accelerate those essential requirements while reducing inefficiencies and costs across the gene therapy CMC process, ultimately facilitating broader access to gene therapy treatments," added Gao.
Since the launch of its offerings for gene therapy applications in March this year, Nanomosaic has enabled gene therapy developers to generate novel analytical insights and inform critical decisions in program development..